Brief: MyMD Pharmaceuticals Reports Positive Topline Phase 2 Results Oral TNF-Α Inhibitor
31/07/2023 14:01
July 31 (Reuters) - MyMD Pharmaceuticals Inc MYMD.O :
* MYMD PHARMACEUTICALS REPORTS STATISTICALLY SIGNIFICANT
POSITIVE
TOPLINE PHASE 2 RESULTS FOR NEXT GENERATION ORAL TNF-Α INHIBITOR
MYMD-1® IN SARCOPENIA/AGE-RELATED FRAILTY
* MYMD - MYMD-1 MET ALL PRIMARY PHARMACOKINETIC AND
SECONDARY
SAFETY AND TOLERABILITY ENDPOINTS ACROSS MULTIPLE DOSES OVER 28
DAYS OF TREATMENT
* MYMD - PLANS TO INITIATE DISCUSSIONS WITH FDA REGARDING A
PHASE
3 STUDY OF MYMD-1 IN SARCOPENIA
Source text for Eikon: ID:nBw1wFxZna
Further company coverage: MYMD.O
((Reuters.Briefs@thomsonreuters.com;))